Related to Lilly Buys Avid for $300M for Phase III Amyloid Plaque Imaging Agent

• EMD Millipore Signals Expansion into Flow Cytometry with Amnis Acquisition
  
• Qiagen and Lilly to Co-Develop Companion Diagnostic for JAK2 Inhibitor Candidate
  
• Roche Pays Evotec $10M Up Front in Deal to Develop MAO-B Inhibitor for Alzheimer Disease
  
• Scientists Develop Miniaturized Fluorescence Microscope
  
• Opko Divests Opthalmic Imaging Solutions to Optos for $17.5M
  
• Ipsen Pays PhotoCure and GE Healthcare €19M for Commercialization Rights to Hexvix
  
• Servier Pays $2M to Exercise Option for Alzheimer Drug Candidate Developed with Cortex
  
• FDA Clears Lilly’s Cialis for Treating Symptoms of BPH in Men with or without Erectile Dysfunction
  
• Venture Firms Pump $18M into Fledgling Arteaus Therapeutics
  
• Lilly Pulls Septic Shock Drug Xigris Off the Shelves
  
• Amylin to Pay Lilly $250M to End Exenatide Partnership and Litigation
  
• Elan, Cambridge University Launch CNS Disease Drug Discovery Facility
  
• Odyssey Thera to Use GE Healthcare’s Imaging System
  
• Maven to Leverage Sony DADC Technology in Label-Free Detection
  
• Dana-Farber Licenses Luciferase-Reporter Cancer Cell Lines to Molecular Imaging
  
• Merck & Co. Axes Alzheimer Deal with Acumen, Nabs Exelixis’ PI3K-Delta Program
  
• BMS and Gladstone Partner to Identify Alzheimer Disease Targets
  
• Probiodrug Secures €15M to Progress Glutaminyl Cyclase Inhibitor Alzheimer Drug
  
• Pfizer, Medivation Nix Development of Alzheimer Disease Therapy
  
• Aphios Pockets $2.4M SBIR Grant for Preclinical Alzheimer Disease Candidate